Translational Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa

描述(由申请人提供)：一项多研究者、多中心的研究计划被提出，旨在开发和测试基于基因的视网膜疗法在动物模型(小鼠和狗)中的应用，以翻译到由视紫红质基因(RHO)突变引起的常染色体显性遗传性RP患者。Rho突变构成了人类RP最常见的分子识别原因之一，其中超过100个突变占RP的12%。该提案分为4个目标：(目标1)发展病毒载体、启动子、敲除结构和替换cDNA，并比较Rho基因增强法和非等位基因非依赖敲除和替换策略在两种小鼠模型中的效果；(目标#2)在大型动物模型(狗)中评估这些策略中哪一种可提供最佳的Rho-ADRP抢救策略，(目标#3)为Rho-ADRP患者的基因治疗临床试验制定结果指标，(目标#4)在临床前安全性研究中评估最佳策略和载体构建(基于AIMS#1和2的结果)。描述了六个协调模块(M)，每个模块都有一套特定的目标，这些目标以独特但互补的方式对翻译研究做出了贡献。M1(载体开发)将提供携带击倒(siRNA，核酶)试剂的AAVs和具有抗性(硬化)的Rho cDNA。M2(小动物-小鼠治疗研究)将在两个小鼠模型上测试这两种基因治疗方法。M3(大型动物实验支持)将生产狗，并为这项工作提供基础设施资源)。M4(大型动物I-狗疗法研究)将在自然发生的Rho-ADRP犬模型中测试这两种方法。M5(Human Rho-adrp)将识别可作为患者视网膜局部治疗的目标视网膜区域。M6(动物媒介安全性研究)将在小动物和大动物中进行基于GLP的临床前毒理学和生物分布研究，以测试最佳(“铅”)治疗载体的安全性，这是FDA考虑在未来的I期临床试验中使用IND的重要第一步。该提案中描述的研究代表了模块科学家之间长期合作的继续，该模块科学家已经将RPE65-LCA患者的视网膜基因治疗带入I期临床试验。

DESCRIPTION (provided by applicant): A multi-investigator, multi-center research plan is proposed to develop and test gene-based retinal therapy in animal models (mouse and dog) for translation to patients with autosomal dominant RP caused by mutations in the rhodopsin gene (RHO). RHO mutations constitute one of the most common molecularly-identified causes of human RP, and more than 100 of them account for > 12 % of RP. The proposal has been divided into 4 aims that will: (Aim#1) develop viral vectors, promoters, knockdown constructs and replacement cDNAs, and compare the efficacy of a RHO cDNA augmentation approach, to that of an allele-independent knockdown and replacement strategy in two mouse models; (Aim #2) evaluate in a large animal model (dog) which of these strategies provides optimal rescue of rods, (Aim #3) develop outcome measures for clinical trials of gene therapy in RHO-ADRP patients, and (Aim #4) evaluate the optimal strategy and vector construct (based on results of Aims #1 and 2) in pre-clinical safety studies. Six coordinated modules (M) are described, each with a specific set of aims that contributes in a unique but complementary way to the translational studies. M1 (Vector Development) will provide AAVs carrying knockdown (siRNA, ribozymes) reagents, and resistant (hardened) RHO cDNAs. M2 (Small Animal-mouse- Therapy Studies) will test the 2 gene therapy approaches in two mouse models. M3 (Large Animal Experiemntal Support) will produce the dogs, and provide infrastructure resources for this work). M4 (Large anima I- dog - Therapy Studies) will test the 2 approaches in a naturally -occurring canine model of RHO-ADRP. M5 (Human RHO-ADRP) will identify retinal regions that can be targeted for focal retinal therapy in patients. M6 (Vector safety studies in Animals) will conduct GLP-based preclinical toxicology and biodistribution studies in small and large animals to test the safety of the optimal ("lead") therapeutic vector as the essential first step ro FDA consideration of an IND for a future Phase I Clinical Trial. The research studies described in this proposal represent a continuation of a longstanding collaboration between the module scientists that already has brought retinal gene therapy for RPE65-LCA patients to a Phase I clinical trial.